Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.
Skip Nav Destination
Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma
December 30, 2021
Content License:Private